Neoleukin Therapeutics IncChange company Symbol lookupSelect an option...NLTX Neoleukin Therapeutics IncKHC Kraft Heinz CoVANI Vivani Medical IncOCX OncoCyte CorpMRSN Mersana Therapeutics IncBDRX Midatech Pharma PLCMTP Midatech Pharma PLCDFUSX DFA U.S. Large Company PortfolioTHST Truett-Hurst IncGPN Global Payments IncGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.
|
|
|
|
| |
Company Profile
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 0.28x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Todd E. Simpson
- Jonathan G. DrachmanPres.
- Donna M. CochenerSr.VP
- Carl WalkeySr.VP
- Bill ArthurVP
Address
- 1616 Eastlake Ave E Ste 360
- Seattle, WA 98102-3795
- Phone: (206) 732-2133
- Fax: (302) 655-5049
- https://www.neoleukin.com/
Insider Trading
During the most recent quarter, 18K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.